Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag

Virology

Volumn 342, Issue 1, 2005, Pages 1-12

  Zhao, Jun ^a   Voltan, Rebecca ^a   Peng, Bo ^a   Davis Warren, Alberta ^a   Kalyanaraman, V S ^b   Alvord, W Gregory ^c   Aldrich, Kris ^a   Bernasconi, Daniela ^d   Buttò, Stefano ^d   Cafaro, Aurelio ^d   Ensoli, Barbara ^d   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Adenovirus recombinant; AIDS vaccine; HIV Tat

Indexed keywords

ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE; TRANSACTIVATOR 22 PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; WILD TYPE;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; DNA, RECOMBINANT; FEMALE; GENE PRODUCTS, GAG; GENE PRODUCTS, TAT; GENES, GAG; GENES, TAT; GENETIC VECTORS; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON TYPE II; MACACA MULATTA; MICE; MICE, INBRED BALB C; MUTATION; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

ADENOVIRIDAE; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 27444438444     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2005.07.016     Document Type: Article

References (62)

1. T.M. Allen, D.H. O'Connor, P. Jing, J.L. Dzuris, B.R. Mothe, T.U. Vogel, E. Dunphy, M.E. Liebl, C. Emerson, N. Wilson, K.J. Kunstman, X. Wang, A.D. Hughes, A.L. Desrosiers, R.C. Altman, J.D. Wolinsky, S.M. Sette, and A. Watkins Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia Nature 407 2000 386 390
2. G. Barillari, and B. Ensoli Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma Clin. Microbiol. Rev. 15 2002 310 326
3. S.L. Buge, E. Richardson, S. Alipanah, P. Markham, S. Cheng, N. Kalyan, C.J. Miller, M. Lubeck, S. Udem, J. Eldridge, and M. Robert-Guroff An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge J. Virol. 71 1997 8531 8541
4. S. Butto, V. Fiorelli, A. Tripiciano, M.J. Ruiz-Alvarez, A. Scoglio, F. Ensoli, M. Ciccozzi, B. Collacchi, M. Sabbatucci, A. Cafaro, C.A. Guzman, A. Borsetti, A. Caputo, E. Vardas, M. Colvin, M. Lukwiya, G. Rezza, B. Ensoli Tat Multicentric Study Group Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans J. Infect. Dis. 188 2003 1171 1180
5. A. Cafaro, A. Caputo, C. Fracasso, M.T. Maggiorella, D. Goletti, S. Baroncelli, M. Pace, L. Sernicola, M.L. Koanga-Mogtomo, M. Betti, A. Borsetti, R. Belli, L. Akerblom, F. Corrias, S. Butto, J. Heeney, P. Verani, F. Titti, and B. Ensoli Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine Nat. Med. 5 1999 643 650
6. A. Caputo, M.P. Grossi, R. Bozzini, C. Rossi, M. Betti, P.C. Marconi, G. Barbanti-Brodano, and P.G. Balboni Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region Gene Ther. 3 1996 235 245
7. A. Caputo, R. Gavioli, and B. Ensoli Recent advances in the development of HIV-1 Tat-based vaccines Curr. HIV Res. 2 2004 357 376
8. E. Caselli, M. Betti, M.P. Grossi, P.G. Balboni, C. Rossi, C. Boarini, A. Cafaro, G. Barbanti-Brodano, B. Ensoli, and A. Caputo DNA immunization with HIV-1 tat mutated in the transactivation domain induces humoral and cellular immune responses against wild-type Tat J. Immunol. 162 1999 5631 5638
9. H.K. Chang, R.C. Gallo, and B. Ensoli Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein J. Biomed. Sci. 2 1995 189 202
10. H.C. Chang, F. Samaniego, B.C. Nair, L. Buonaguro, and B. Ensoli HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region AIDS 11 1997 1421 1431
11. M. Chengalvala, M.D. Lubeck, A.R. Davis, S. Mizutani, K. Molnar-Kimber, J. Morin, and P.P. Hung Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs Vaccine 9 1991 485 490
12. S.S. Cohen, C. Li, L. Ding, Y. Cao, A.B. Pardee, E.M. Shevach, and D.I. Cohen Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge Proc. Natl. Acad. Sci. U.S.A. 96 1999 10842 10847
13. D.H. Dockrell, A.D. Badley, J.S. Villacian, C.J. Heppelmann, A. Algeciras, S. Ziesmer, H. Yagita, D.H. Lynch, P.C. Roche, P.J. Leibson, and C.V. Paya The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection J. Clin. Invest. 101 1998 2394 2405
14. B. Ensoli, and A. Cafaro Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus AIDS Clin. Rev. 1 2000-01 23 61
15. E. Fanales-Belasio, S. Moretti, F. Nappi, G. Barillari, F. Micheletti, A. Cafaro, and B. Ensoli Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses J. Immunol. 168 1 2002 197 206
16. R.C. Gallo Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine Proc. Natl. Acad. Sci. U.S.A. 96 1999 8324 8326
17. R. Gavioli, E. Gallerani, C. Fortini, M. Fabris, A. Bottoni, A. Canella, A. Bonaccorsi, M. Marastoni, F. Micheletti, A. Cafaro, P. Rimessi, A. Caputo, and B. Ensoli HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity J. Immunol. 173 2004 3838 3843
18. G. Goldstein HIV-1 Tat protein as a potential AIDS vaccine Nat. Med. 2 1996 960 964
19. 33) Vaccine 18 2000 2789 2795
20. G. Goldstein, G. Tribbick, and K. Manson Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains Vaccine 19 2001 1738 1746
21. Z. Hel, J. Nacsa, E. Tryniszewska, W.P. Tsai, R.W. Parks, D.C. Montefiori, B.K. Felber, J. Tartaglia, G.N. Pavlakis, and G. Franchini Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses J. Immunol. 169 2002 4778 4787
22. D.D. Ho, and Y. Huang The HIV-1 vaccine race Cell 10 2002 135 138
23. E. Izmailova, F.M.N. Bertley, Q. Huang, N. Makori, C.J. Miller, R.A. Young, and A. Aldovini HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages Nat. Med. 9 2003 191 197
24. D.T. Kim, D.J. Mitchell, D.G. Brockstedt, L. Fong, G.P. Nolan, C.G. Fathman, E.G. Engleman, and J.B. Rothbard Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide J. Immunol. 159 1997 1666 1668
25. V. Kolesnitchenko, L. King, A. Riva, Y. Tani, S.J. Korsmeyer, and D.I. Cohen A major human immunodeficiency virus type 1-initiated killing pathway distinct from apoptosis J. Virol. 71 1997 9753 9763
26. W. Kong, Y. Huang, Z. Yang, B.K. Chakrabarti, Z. Moodie, and G.J. Nabel Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines J. Virol. 77 2003 12764 12772
27. E.A. Lefevre, R. Krzysiek, E.P. Loret, P. Galanaud, and Y. Richard Cutting edge: HIV-1 Tat protein differentially modulates the B cell response of naïve, memory, and germinal center B cells J. Immunol. 163 1999 1119 1122
28. J.A. Leifert, P.D. Holler, S. Harkins, D.M. Kranz, and J.L. Whitton The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes Gene Ther. 10 2003 2067 2073
29. N. Letvin, D.H. Barouch, and D.C. Montefiori Prospects for vaccine protection against HIV-1 infection and AIDS Ann. Rev. Immunol. 20 2002 73 99
30. C.J. Li, D.J. Friedman, C. Wang, V. Metelev, and A.B. Pardee Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein Science 268 1995 429 431
31. M. Lindgren, M. Hallbrink, A. Prochiantz, and U. Langel Cell-penetrating peptides Trends Pharmacol. Sci. 21 2000 99 103
32. M.D. Lubeck, R.J. Natuk, M. Myagkikh, N. Kalyan, K. Aldrich, F. Sinangil, S. Alipanah, S.C.S. Murthy, P.K. Chanda, S. Nigida, P.D. Markham, S. Zolla-Pazner, K. Steimer, M. Wade, M.S. Reitz Jr., L.O. Arthur, S. Mizutani, A. Davis, P. Hung, R.C. Gallo, J. Eichberg, and M. Robert-Guroff Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization Nat. Med. 3 1997 651 658
33. M.T. Maggiorella, S. Baroncelli, Z. Michelini, E. Fanales-Belasio, S. Moretti, L. Sernicola, A. Cara, D.R. Negri, S. Butto, V. Fiorelli, A. Tripiciano, A. Scoglio, A. Caputo, A. Borsetti, B. Ridolfi, R. Bona, P. ten Haaft, I. Macchia, P. Leone, M.R. Pavone-Cossut, F. Nappi, M. Ciccozzi, J. Heeney, F. Titti, A. Cafaro, and B. Ensoli Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys Vaccine 22 2004 3258 3269
34. B. Makitalo, P. Lundholm, J. Hinkula, C. Nilsson, K. Karlen, A. Morner, G. Sutter, V. Erfle, J.L. Heeney, B. Wahren, G. Biberfeld, and R. Thorstensson Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen J. Gen. Virol. 85 2004 2407 2419
35. N.V. Malkevitch, and M. Robert-Guroff A call for replicating vector prime-protein boost strategies in HIV vaccine design Exp. Rev. Vaccines 3 2004 89 101
36. A.J. McMichael, and S.L. Rowland-Jones Cellular immune responses to HIV Nature 410 2001 980 987
37. P. Mooij, I.G. Nieuwenhuis, C.J. Knoop, R.W. Doms, W.M.J.M. Bogers, P.J.F. ten Haaft, H. Niphuis, W. Koornstra, K. Bieler, J. Kostler, B. Morein, A. Cafaro, B. Ensoli, R. Wagner, and J.L. Heeney Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection J. Virol. 78 2004 3333 3342
38. S.P. Mossman, C.C. Pierce, A.J. Watson, M.N. Robertson, D.C. Montefiori, L. Kuller, B.A. Richardson, J.D. Bradshaw, R.J. Munn, S.L. Hu, P.D. Greenberg, R.E. Benveniste, and N.L. Haigwood Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles AIDS Res. Hum. Retrovir. 20 2004 425 434
39. P. Moy, Y. Daikh, B. Pepinsky, D. Thomas, S. Fawell, and J. Barsoum Tat-mediated protein delivery can facilitate MHC class I presentation of antigens Mol. Biotechnol. 6 1996 105 113
40. K. Muthumani, M. Bagarazzi, D. Conway, D.S. Hwang, V. Ayyavoo, D. Zhang, K. Manson, J. Kim, J. Boyer, and D.B. Weiner Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques J. Med. Primatol. 31 2002 179 185
41. V.D.R. Negri, S. Baroncelli, S. Catone, A. Comini, Z. Michelini, M.T. Maggiorella, L. Sernicola, F. Crostarosa, R. Belli, M.G. Mancini, S. Farcomeni, Z. Fagrouch, M. Ciccozzi, S. Boros, P. Liljestrom, S. Norley, J. Heeney, and F. Titti Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge J. Gen. Virol. 85 2004 1191 1201
42. A.D. Osterhaus, C.A. van Baalen, R.A. Gruters, M. Schutten, C.H. Siebelink, E.G. Hulskotte, E.J. Tijhaar, R.E. Randall, G. van Amerongen, A. Fleuchaus, V. Erfle, and G. Sutter Vaccination with Rev and Tat against AIDS Vaccine 17 1999 2713 2714
43. I. Ourmanov, M. Bilska, V.M. Hirsch, and D.C. Montefiori Recombinant modified vaccinia virus Ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques J. Virol. 74 2000 2960 2965
44. L.J. Patterson, N. Malkevitch, J. Zhao, B. Peng, and M. Robert-Guroff Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef DNA Cell Biol. 21 2002 627 635
45. L.J. Patterson, N. Malkevitch, J. Pinczewski, D. Venzon, Y. Lou, B. Peng, C. Munch, M. Leonard, E. Richardson, K. Aldrich, V.S. Kalyanaraman, G.N. Pavlakis, and M. Robert-Guroff Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIVgp120 J. Virol. 77 2003 8607 8620
46. L.J. Patterson, N. Malkevitch, D. Venzon, J. Pinczewski, V.R. Gomez-Roman, L. Wang, V.S. Kalyanaraman, P.D. Markham, F.A. Robey, and M. Robert-Guroff Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting J.Virol. 78 2004 2212 2221
47. C.D. Pauza, P. Trivedi, M. Wallace, T.J. Ruckwardt, H. Le Buanec, W. Lu, B. Bizzini, A. Burny, D. Zagury, and R.C. Gallo Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques Proc. Natl. Acad. Sci. U.S.A. 97 2000 3515 3519
48. M.C. Re, M. Vignoli, G. Furlini, D. Gibellini, V. Colangeli, F. Vitone, and M. La Placa Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients J. Clin. Virol. 21 2001 81 89
49. P. Reiss, J.M. Lange, A. de Ronde, F. de Wolf, J. Dekker, C. Debouck, and J. Goudsmit Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1 J. Med. Virol. 30 1990 163 168
50. G. Rezza, V. Fiorelli, M. Corrucci, M. Coccozzi, A. Tripiciano, A. Scoglio, B. Collacchi, M. Ruiz-Alvarez, C. Giannetto, A. Caputo, L. Tomasoni, F. Casteli, M. Sciandra, A. Sinicco, F. Encoli, S. Butto, and B. Ensoli The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters J. Infect. Dis. 191 2005 1321 1324
51. M.W. Richardson, J. Mirchandani, P. Silvera, E.G. Regulier, C. Capini, P.M. Bojczuk, J. Hu, E.J. Gracely, J.D. Boyer, K. Khalili, J.-F. Zagury, M.G. Lewis, and J. Rappaport Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses DNA Cell Biol. 21 2002 637 651
52. M. Robert-Guroff HIV regulatory and accessory proteins: new targets for vaccine development DNA Cell Biol. 21 2002 597 598
53. T.J. Ruckwardt, I. Tikhonov, S. Berg, G.S. Hatfield, A. Chandra, P. Chandra, B. Gilliam, R.R. Redfield, R.C. Gallo, and C.D. Pauza Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein J. Virol. 78 2004 13190 13196
54. P. Silvera, M.W. Richardson, J. Greenhouse, J. Yalley-Ogunro, N. Shaw, J. Mirchandani, K. Khalili, J.F. Zagury, M.G. Lewis, and J. Rappaport Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein J. Virol. 76 2002 3800 3809
55. I. Tikhonov, T.J. Ruckwardt, G.S. Hatfield, and C.D. Pauza Tat-neutralizing antibodies in vaccinated macaques J. Virol. 77 2003 3157 3166
56. C.A. van Baalen, O. Pontesilli, R.C. Huisman, A.M. Geretti, M.R. Klein, F. de Wolf, F. Miedema, R.A. Gruters, and A.D. Osterhaus Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS J. Gen. Virol. 78 1997 1913 1918
57. B. Verrier, R. Le Grand, Y. Ataman-Onal, C. Terrat, C. Guillon, P.Y. Durand, B. Hurtrel, A.-M. Aubertin, G. Sutter, V. Erfle, and M. Girard Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08 DNA Cell Biol. 21 2002 653 658
58. Y. Wu, and J.W. Marsh Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA Science 293 2001 1503 1506
59. M.X. Wu, and S.F. Schlossman Decreased ability of HIV-1 tat protein-treated accessory cells to organize cellular clusters is associated with partial activation of T cells Proc. Natl. Acad. Sci. U.S.A. 94 1997 13832 13837
60. J.F. Zagury, A. Sill, W. Blattner, A. Lachgar, H. Le Buanec, M. Richardson, J. Rappaport, H. Hendel, B. Bizzini, A. Gringeri, M. Carcagno, M. Criscuolo, A. Burny, R.C. Gallo, and D. Zagury Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine J. Hum. Virol. 1 1998 282 292
61. J. Zhao, Y. Lou, J. Pinczewski, N. Malkevitch, K. Aldrich, V.S. Kalyanaraman, D. Venzon, B. Peng, L.J. Patterson, Y. Edghill-Smith, R. Woodward, G.N. Pavlakis, and M. Robert-Guroff Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants Vaccine 21 2003 4022 4035
62. J. Zhao, J. Pinczewski, V.R. Gomez-Roman, D. Venzon, V.S. Kalyanaraman, P.D. Markham, K. Aldrich, M. Moake, D.C. Montefiori, Y. Lou, G.N. Pavlakis, and M. Robert-Guroff Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen J. Virol. 77 2003 8354 8365